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T
EGlucopyranosylidene-spiro-1,4,2-oxathiazoles were prepared in high yields by NBS-mediated spiro-cycli-
zation of the corresponding glucosyl-hydroximothioates. In an effort to synthesize analogous glucopyr-
anosylidene-spiro-1,2,4-oxadiazolines, with a nitrogen atom instead of the sulphur, attempted
cyclizations resulted in aromatization of the heterocycle with opening of the pyranosyl ring. Enzymatic
measurements showed that some of the glucose-based inhibitors were active in the micromolar range.
The 2-naphthyl-substituted 1,4,2-oxathiazole displayed the best inhibition against RMGPb (Ki = 160 nM),
among glucose-based inhibitors known to date.
 2009 Published by Elsevier Ltd.R60
70U
N
C
O1. Introduction
Type 2 diabetes mellitus1 is currently estimated to affect more
than 5% of the adult population in Western societies, and its inci-
dence is expected to increase considerably in the future.2,3 This is
in particular due to the dramatic increase in obesity even among
young adults and children.4–6 Striking enhancements in the preva-
lence of the disease is predicted for the developing countries of
Africa, Asia, and South America.2 Current preventive and therapeu-
tic strategies do not achieve adequate control of blood glucose to
diminish chronic morbidity, and there is a need to develop novel
healthcare interventions to address this substantial biomedical
challenge.7Elsevier Ltd.
x: +33 4 72 44 83 49 (J.-P.P.).
-P. Praly).
; et al. Bioorg. Med. Chem. (2Hepatic glucose output is elevated in type 2 diabetic patients
and current evidence indicates that glycogenolysis (release of
monomeric glucose from the glycogen polymer storage form) is
an important contributor to the abnormally high production of glu-
cose by the liver. Glycogen phosphorylase (GP) is the rate limiting
enzyme in the liver responsible for glycogen breakdown to pro-
duce glucose and related metabolites for energy supply.8 Due to
its key role in modulation of glycogen metabolism, pharmacologi-
cal inhibition of GP has been regarded as an effective therapeutic
approach to treating type 2 diabetes.9–11
Several types of compounds for inhibition of GP have been re-
ported,10–13 and among them derivatives of D-glucose represent,
as ligands of the catalytic site, the most populated class (Chart
1).12–15 There are three mammalian GP isoenzymes termed as
‘brain’, ‘muscle’, or ‘liver’ GP depending on the tissue in which they
are preferentially expressed. All isoenzymes can be converted from
the inactive form (GPb) into the active GPa form through the phos-009), doi:10.1016/j.bmc.2009.05.080
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Chart 1. Inhibitory constants (Ki [lM]) for some representative inhibitors of rabbit muscle glycogen phosphorylase.24,25,27
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Ophorylation of Ser-14. Isoforms of GP can be obtained from rabbitsqueletal muscles (RMGPa/RMGPb) or human liver (HLGPa/HLGPb). Because of a 80% homology between the liver and mus-
cle isoforms of GP, it is a general practice to use the more readily
available RMGP (most frequently in the unphosphorylated b form)
for preliminary kinetic studies (Chart 1), even though, for in vivo
experiments, the existence of isoforms raises the question of the
selectivity of inhibition.13 The functional form of GP is a homodi-
mer having a C-2 symmetry. The catalytic site of GP is buried at
the centre of the monomers, and is accessible to the bulk solvent
through a 15 Å long channel. The site has been extensively investi-
gated with glucose analogue inhibitors which promote the less ac-
tive T (tensed) state through stabilisation of the closed position of
the 280s loop. Upon transition from the T state to the R (relaxed)
state, the 280s loop becomes disordered and displaced, resulting
in the activation of the enzyme. Crystallographic investigations
have shown the existence of an empty pocket in the direction of
the b-anomeric substituent of D-glucopyranose, lined by both polar
and non-polar group, and named the b-channel.10
N-Acetyl-b-D-glucopyranosylamine16 A was one of the ﬁrst efﬁ-
cient glucose analogue inhibitors of GP. A large array of compoundsPlease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (2with the N-acyl-b-D-glucopyranosylamine structure (e.g., B–F) was
synthesized, tested, and also investigated by X-ray crystallogra-
phy.10 These studies revealed that a H-bridge between the amide
NH and main chain CO of His377 (Chart 1) signiﬁcantly contributed
to the binding. This H-bridge was also observed in GP crystal com-
plexes of the low micromolar inhibitor spiro-hydantoins G17 and
H,18 and was, thereby, considered to be an essential feature for
strong inhibition. The rigidity of the spiro-bicyclic structure of
the latter compounds with a pyranoid sugar and a ﬁve-membered
heterocyclic ring was also considered to be a decisive factor for the
efﬁciency.17 On the other hand, N-b-D-glucopyranosyl-N0-acyl ur-
eas12,13,19 (e.g., I–M) with large aromatic acyl moieties (K,M) prop-
erly oriented so as to interact with the side chains of the so-called
b-channel next to the catalytic site, exhibit nanomolar inhibi-
tion12,13,20 despite the lack of the H-bond mentioned above. There-
fore, interactions in the so called b-channel of the enzyme must
play a more important role than that particular H-bond.
Based on the binding peculiarities of these inhibitors, we envis-
aged to prepare compounds which might unify the structural fea-
tures of the best inhibitors, that is, spiro junction between the
anomeric carbon of D-glucopyranose and a ﬁve-membered hetero-009), doi:10.1016/j.bmc.2009.05.080
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cycle, as well as a large aromatic substituent capable of interac-
tions in the b-channel. This design was supported by the ﬁnding
that spiro-oxathiazole N, available from earlier synthetic stud-
ies,21,22 proved to be a micromolar inhibitor. Therefore, synthesis
of further compounds of this series was carried out23 and, in order
to facilitate the formation of an additional H-bond, preparation of
spiro-oxadiazolines of type O was also attempted.
2. Results and discussion
2.1. Preparation of glucosyl-hydroximothioates
The D-glucosyl hydroximothioates 1a–j were prepared from
per-O-acetylated 1-thio-b-D-glucopyranose and in situ formed ni-
trile oxides used in slight excess (1.2 equiv), following a procedure
reported previously by Rollin32 (Scheme 1, Table 1). The synthesis
of 1i (Ar = 4-pyridyl) was optimized by increasing the amount of 4-
pyridyl-hydroximoyl chloride used for producing the correspond-
ing nitrile oxide with yields growing as follows: 6% (1.4 equiv),
48% (3.8 equiv), 78% (5 equiv). The prepared hydroximothioates
which appeared to be stable under normal conditions were deacet-
ylated by standard procedures (NaOMe/MeOH or MeOH/H2O/Et3N)
to afford the corresponding unprotected products in high yields
(Scheme 1).
In an attempt to prepare molecules susceptible to bind more
tightly at the active site of GP through non covalent interactions
involving a polar group near the anomeric center of the ligand,
we tried to oxidize compound 1i (Ar = 4-pyridyl) with m-CPBA,
as applied earlier for the synthesis of glucosyl-phenyl-sulfoxides.33
The oxidation was not selective, since the reaction mixture was
shown by TLC to contain a mobile compound, and two major polar
products. One of them was shown to be the N-oxide 1j (Ar = 4-pyr-
idyl-N-oxide), isolated in ca 30% yield.
2.2. NBS-mediated cyclization of hydroximothioates
The spiro-cyclization of phenyl hydroximothioate 1a proceeded
in CHCl3 with the same selectivity as already observed in CCl4,22,33
affording a 5:1 mixture of the (1S)/(1R)-epimers of 2a (Scheme 1).
The reaction of hydroximothioates 1b,c,e,g,hwith N-bromosuccin-
imide (NBS) in freshly distilled CCl4 or CHCl3 was stopped when
TLC monitoring indicated complete conversion of the substrates,
ca 45 min at reﬂux under irradiation with a tungsten lamp
(60 W). This afforded the spiro-bicycles 3b,c,e,g,h as a mixture of
epimers, with the predominance of the (1S)-conﬁgured com-
pounds. Separation by ﬂash column chromatography afforded ﬁrst
the pure (1S)-epimers. The fractions collected next contained epi-
meric mixtures whose composition was estimated by 1H NMR to
permit calculation of the yield for each epimer (Table 1). ThisU
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Scheme 1. Synthesis of D-glucopyranosylidene-spiro-oxathiazoles. Reagents and
conditions: (a) ArC(Cl) = NOH, Et3N; (b) NaOMe, MeOH, or MeOH, Et3N, H2O, rt; (c)
NBS, hm, 45 min, in reﬂuxing CCl4 or CHCl3.
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spiro-cyclization is believed to proceed through a 1,5-hydrogen
transfer to alkoxyl radicals to create predominantly a oriented
C–O bonds.34,35 Spiro-cyclization of 1f was not selective under
the applied conditions (heating for 1 h with a lamp), yielding a
multicomponent mixture. Among the four fractions obtained by
column chromatography, only the third one was pure enough to
get exploitable NMR data corresponding probably to the (1R)-3f
spiro compound, because of the observed pattern of the proton sig-
nals resonating at d = 5.59, 5.10, 5.27 and 4.10 ppm for protons H-
2, H-3, H-4 and H-5, respectively (in CDCl3).
Treatment of 1i with NBS (2 equiv) in boiling chloroform for
30 min resulted in the formation of two major and two minor com-
pounds (TLC). Column chromatography afforded only one homoge-
neous fraction identiﬁed as (1R)-3i (30%), based on NMR data and
the fact that (1R)-epimers were found to be signiﬁcantly more dex-
trorotatory than the (1S)-epimers.22,33 Since spiro-cyclization
afforded in this case a higher proportion of the (1R)-epimer, we
wondered whether this was due to the basic properties of pyridine.
Therefore, the spiro-cyclization of 1a (Ar = phenyl) was carried out
in the presence of DBU (1 equiv) affording 2a (34% yield) in a 1:1
(1S)/(1R) ratio after repeated column chromatographies. As com-
pared to the selectivity normally observed (60% yield, 5:1 (1S)/
(1R) ratio), this change suggested a variation along the possible
reaction pathways.
The Zemplén deacetylation was achieved in high yields to ob-
tain the desired spiro-oxathiazoles 4b,c,e,g,h. The ﬁnal products
had a very poor solubility in H2O, MeOH, EtOH (less than 0.1 mg/
mL) but were soluble in DMF or DMSO.
2.3. Attempted preparations of glucosylidene-spiro-1,2,4-
oxadiazolines
The synthesis of glucosylidene-spiro-1,2,4-oxadiazolines was
planned as nitrogen-containing spiro analogues by applying again
a NBS-mediated cyclization reaction to N-b-D-glucosyl-amidox-
imes 8 (Scheme 2). A detailed retrosynthetic analysis and the prep-
aration of the amidoximes36 are presented in the Supporting
Information. Preparation of the required amidoxime 8 from per-
O-acetylated glucopyranosyl bromide 5 or glucopyranosylamine
6 failed. Fortunately, in the presence of trimethylphosphine, acety-
lated b-D-glucopyranosyl azide 7 was transformed into the corre-
sponding phosphinimine derivative37 which reacted readily with
hydroximoyl chlorides38–40 and gave the target molecules 8a–c,h.
The NMR spectra of the crude products indicated the presence of
two species (1:10 ratio) assumed to be the E and Z-conﬁgured
isomers. Due to the poor stability of some of these compounds,
only 8b and 8c could be deacetylated by the Zemplén method to
give 9b and 9c.
The oxidative photocyclization of 4-nitrobenzamidoxime 8b
was carried out under conditions similar to those applied in the
synthesis of spiro-oxathiazoles 3. A chloroform solution of 8b
and NBS was irradiated with a heating lamp (60 or 375W). NBS
(4 equiv, twice as much as for the oxathiazoles) had to be added
at once or portion wise to completely transform the starting mate-
rial. Three experiments afforded mixtures which did not contain
the expected spiro-molecule IV (Scheme 2) but separation by col-
umn chromatography afforded 10b, 11b, and 12b in variable pro-
portions (Table 2). Nitroso compound 10b should result from 8b
by oxidation without cyclization. However, formation of 11b and
12b clearly indicated that spiro-cyclization must have occurred
followed by ring opening of the pyranosyl ring to allow aromatiza-
tion of the oxadiazole ring. Compound 12b displayed in addition a
carbonyl due to oxidation of the liberated hydroxyl at C-5. The
product distribution was highly dependent on the applied condi-
tions which were not optimized, although it was possible to obtain
12b as a single product.009), doi:10.1016/j.bmc.2009.05.080
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Table 1
Preparation of hydroximothioates 1–2 and glucosylidene-spiro-oxathiazoles 3–4
Ar= Compound/yielda (%)
Ph 2a/9432 1a/9032 (1S)-3a/46 (1R)-3a/11 (1S)-4a/90
p-NO2Ph 2b/9132 1b/6032 (1S)-3b/33 (1R)-3b/16 (1S)-4b/71
p-CNPh (1S)-3c/15 (1R)-3c/7 (1S)-4c/84
p-FPh 2d/9532 1d/6532 (1S)-3d/3022 (1R)-3d/1622 (1S)-4d/79
p-MeOPh 2e/9732 1e/7132 (1S)-3e/69 (1R)-3e/17 (1S)-4e/79
3,4,5-triMeOPh 1f/85 Unselective reaction
p-PhPh (1S)-3g/61 (1R)-3g/18 (1S)-4g/97
2-Naphthyl (1S)-3h/36 (1R)-3h/16 (1S)-4h/94
4-Pyridyl 2i/90 1i/78 (1S)-3i/0 (1R)-3i/30 (1R)-4i/95
4-Pyridyl-N-oxide 1j/30
a Calculated yields given in italics take into account the ratio of anomers estimated by 1H NMR in mixed fractions after puriﬁcation.
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Scheme 2. Attempted preparations of glucosylidene-spiro-oxadiazolines IV. Reagents and conditions: (a) i) PMe3, ii) ArC(Cl) = NOH, Et3N; (b) NaOMe, MeOH; (c) see
conditions in Table 2.
Table 2
Photolysis of 8b under various conditions
Lamp (W) NBS (equiv) Yield of 10b (%) Yield of 11b (%) Yield of 12b (%)
60 4 31 0 3
60 4  1 0 0 45
375 4 0 20 10
4 V. Nagy et al. / Bioorg. Med. Chem. xxx (2009) xxx–xxx
BMC 7568 No. of Pages 12, Model 5G
10 June 2009 Disk Used
ARTICLE IN PRESSU
N
C
O1,3-Dipolar cycloaddition of nitrile oxides to benzyl-protectedglucosyl-hydroximolactone 1341,42 was envisaged as another ap-proach to analogous glycopyranosylidene-spiro-1,2,4-oxadiazo-
lines. Cycloadditions with aryl nitrile oxides derived from a-
chloro-benzaldoxime, a-chloro-4-methoxybenzaldoxime, and a-
chloro-4-nitrobenzaldoxime proved to be disappointing since 13
underwent partial conversion after 24 h in boiling toluene in the
presence of 8 equiv of 4-methoxybenzonitrile oxide. Among the
isolated products (Scheme 3), we could identify the N-oxide dimer
V43 deriving from the nitrile oxide used and 15 (13% isolated yield).
Based on the conversion of 13, the calculated yield for 15 was 22%.
The low reactivity of 13 was conﬁrmed by attempted reactions
with either trimethylsilyldiazomethane in reﬂuxing dioxane, or
with bromonitrile oxide, which resulted only in slow and unselec-
tive transformations. Isolation of V (m/z = 299.1 [M+H]+) proved
the existence, in the reaction mixture, of the 4-methoxybenzoni-
trile oxide which reacted slowly with 13. Mass spectrometry
(ESI) conﬁrmed that cycloaddition took place but it was not appro-
priate to discriminate between structures 14 or 15 which both
might correspond to the observed ions (m/z = 703 [M+H]+). 13C
NMR spectroscopy indicated chemical shifts at 140.8 ppmPlease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (2(N2CAr) and 154.2 ppm (NCO) characteristic of the oxadiazole N-
oxide ring.44 Formation of an aromatic oxadiazole ring with open-
ing of the pyrane ring was in analogy with our previous observa-
tions from attempted spiro-cyclization of benzamidoximes.
2.4. Inhibition of glycogen phosphorylase
Enzymatic tests (Table 3) with deprotected hydroximothioates
2, benzamidoximes 9b,c, and the (1R)-conﬁgured spiro-oxathiazole
(1R)-4i showed no signiﬁcant inhibition of rabbit muscle glycogen
phosphorylase (RMGP) b. In contrast, several (1S)-conﬁgured spiro-
compounds (1S)-4 showed inhibition in the low micromolar range,
except for compounds (1S)-4b,c having polar substituents (4-nitro
and 4-cyano, respectively). The most efﬁcient was the 2-naphthyl
derivative (1S)-4h with a nanomolar Ki which appears to be the
best glucose-based inhibitor known at the moment. This shows
conclusively that a rigid spiro-bicyclic structure, attached to a
properly oriented large apolar aromatic group as the 2-naphthyl
are favorable structural features for strong binding at the catalytic
site of GP. Further exploitation of these ﬁndings is in progress for
the design of more potent inhibitors.
3. Conclusion
The recent identiﬁcation of glycogen phosphorylase as a biolog-
ical target for the treatment of hyperglycemia led to the design of a
large collection of glucose-based inhibitors displaying inhibitory
activities in the micromolar range.10,12–15 Among them, the gluco-
pyranosylidene-spiro-hydantoins28–30 and N-acyl-N0-b-D-glucopyr-
anosyl urea20,31 derivatives were shown to be the best inhibitors.009), doi:10.1016/j.bmc.2009.05.080
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Scheme 3. Attempted cyclization of glucosyl-hydroximolactone 13.
Table 3
Inhibition of rabbit muscle glycogen phosphorylase (RMGP) b
Compound Inhibition (lM) Compound Inhibition (lM)
2b IC50 > 10 000 (1S)-4a Ki = 26
2c No inhibition at 625 (1S)-4b IC50 = 250
2e No inhibition at 312.5 (1S)-4c IC50 = 700
2g Insoluble in DMSO (1S)-4d Ki = 48
2h Insoluble in DMSO (1S)-4e Ki = 8.2
2i No inhibition at 625 (1S)-4g IC50 = 250
9b No inhibition at 625 (1S)-4h Ki = 0.16
9c Ki = 1 800 (1R)-4i No inhibition at 625
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Based on the binding peculiarities of these types of inhibitors as re-
vealed by X-ray crystallography, we set up a new design principle
towards better inhibitors.23 To validate this approach, we designed
a synthesis of properly substituted glucopyranosylidene-spiro-
oxathiazoles by NBS-mediated spiro-cyclization at the anomeric
center of glucopyranosyl-hydroximothioate precursors. Attempted
preparations of the corresponding aza-analogs, in which the sul-
phur atom is replaced by a nitrogen, failed and led to heteroaro-
matic structures with an acyclic carbohydrate moiety. The 2-
naphthyl substituted glucopyranosylidene-spiro-oxathiazole dis-
played the strongest inhibition with a Ki value of 160 nM. The pres-
ent study provides the best inhibitor of GP in the glucose-based
family and strengthens the need for additional investigations to-
wards inhibition of this enzyme.
4. Experimental
4.1. General methods
Dichloromethane, chloroform and carbon tetrachloride were
washed with water (3 times), then dried (CaCl2) prior distillation
over CaH2, and kept away from light. Triethylamine and water were
distilled twice. Thin-layer chromatography (TLC) was carried out on
aluminum sheets coated with Silica Gel 60 F254 (Merck). TLC plates
were inspected by UV light (k = 254 nm) and developed by treat-
ment with a mixture of 10% H2SO4 in EtOH/H2O (1/1 v/v) followed
by heating. Brominated compounds were visualized on TLC plates
by spraying ﬁrst a 0.1% w/v ﬂuorescein solution in absolute MeOH,
then a 1:1 mixture of H2O2 (30% in water) and AcOH. Upon gentle
heating, bromo-compounds gave pink-colored spots. Silica gel col-
umn chromatography was performed with Geduran Silica Gel Si
60 (40–63 lm) purchased from Merck (Darmstadt, Germany). Pre-
parative reversed phase chromatography (RP-18) was performed
using a 15  150 mm column of fully endcapped Silica Gel 100 C18
(>400 mesh, Fluka). 1H and 13C NMR spectra were recorded atPlease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (2E
D
P
R
O23 CusingBrukerDRX300orDRX500spectrometerswith the resid-ual solvent as the internal standard. The following abbreviations are
used to explain the observedmultiplicities: s, singlet; d, doublet; dd,
doublet of doublet; ddd, doublet of doublet of doublet; t, triplet; td,
triplet of doublet; q, quadruplet; m, multiplet; br, broad; p, pseudo.
Structure elucidation was deduced from 1D and 2D NMR spectros-
copy which allowed, in most cases, complete signal assignments
based on COSY, HSQC, and HMBC correlations. Atom numbering fol-
lows that of the parent carbohydrate for the description of the sugar
signals in the NMR spectra. Uncertain assignments are indicated by
an asterisk. NMR solvents were purchased from Euriso-Top (Saint
Aubin, France). HRMS (LSIMS)mass spectrawere recorded in the po-
sitive mode using a Thermo Finnigan Mat 95 XL spectrometer. MS
(ESI)mass spectrawere recorded in the positivemode (unless stated
otherwise) using a Thermo Finnigan LCQ spectrometer. Optical rota-
tions were measured using a Perkin Elmer polarimeter. A collection
of compounds 1 and 2 have been previously described except for
their 13C NMR data.32 1-Thio-b-D-glucopyranosyl hydroximothio-
ates 2a,b,d,e were previously reported.32 Compound (1S)-3d was
previously reported.22
4.1.1. General procedure A for the preparation
of O-peracetylated hydroximothioates 1
Preparation adapted from previously reported procedures.21,32
2,3,4,6-Tetra-O-acetyl-1-thio-b-D-glucopyranose (1 mmol) and
hydroximoyl chloride (1.2 mmol, 1.2 equiv) were dissolved in
CH2Cl2 (5 mL). After adding triethylamine (3 mmol, 3 equiv), the
mixture was stirred at room temperature and TLC monitoring
showed completion of the reaction. The solvent was evaporated
and the residue puriﬁed by ﬂash silica gel column chromatography
(PE/EtOAc 1:1, then 2:3) to afford the desired hydroximothioates 1.
4.1.2. General procedure B for the preparation of deacetylated
compounds 2i and (1R)-4i
The acetylated compound (0.25 mmol) was dissolved in a mix-
ture of water (5 mL), MeOH (5 mL) and triethylamine (1 mL). After
stirring overnight at room temperature, TLC showed deacetylation
was complete. Evaporation of the volatiles under reduced pressure
afforded a residue corresponding to pure deacetylated product.
4.1.3. General procedure C for the preparation of spiro-
oxathiazoles 3
A solution of hydroximothioate 1 (1 mmol) and N-bromosuccin-
imide (2 mmol) in CCl4 (20 mL, for 3b–e,g,h) or CHCl3 (20 mL for
3a,f,i) was boiled and illuminated by a 60 W heat lamp for
45 min. The reaction was diluted with EtOAc (150 mL) and the or-
ganic layer was washed with 5% aqueous Na2SO3 (2  100 mL) and
water (2  100 mL), dried (Na2SO4), ﬁltered and evaporated under009), doi:10.1016/j.bmc.2009.05.080
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reduced pressure. The residue was puriﬁed by ﬂash column chro-
matography (PE then PE/EtOAc 65:35) to afford the desired acety-
lated spiro-oxathiazole 3.
4.1.4. General procedure D for the Zemplén deacetylation
A solution of an acetylated compound 1 or 3 (150 mg) and
NaOMe (5 mg) in MeOH (15 mL) was stirred at rt for 3 h. The reac-
tion was neutralized to pH 5–6 with Amberlite IR-120 resin (H+
form) and the resin washed with MeOH (2  10 mL). The ﬁltrate
was evaporated under reduced pressure to afford the desired
hydroximothioates 2 and spiro-oxathiazoles 4, respectively.
4.1.5. General procedure E for the synthesis of N-glycosyl-
amidoximes 8
Trimethyl phosphine (2.68 mL, 1 M in toluene) was added with
stirring to a solution of 2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl
azide 7 (1 g, 2.68 mmol) in dry dichloromethane (10 mL). After
gas evolution had ceased and TLC showed complete transformation
of the starting azide 7 (10–15 min), a hydroximoyl chloride
(1 equiv) was added. After 20–30 min, the reaction mixture was
poured into water, and the organic layer was separated. The aque-
ous layer was extracted with dichloromethane (2  20 mL). The or-
ganic layers were combined, washed with 10% aq sodium
carbonate and water (5  20 mL), dried (Na2SO4), ﬁltered and
evaporated. The residue was puriﬁed by ﬂash column chromatog-
raphy (EtOAc/hexane, 1:3) or crystallization. An optimized synthe-
sis of 8c is also presented below.
4.2. Synthesis of O-peracetylated hydroximothioates 1
4.2.1. 2,3,4,6-Tetra-O-acetyl-1-S-(Z)-4-nitrobenzhydroximoyl-1-
thio-b-D-glucopyranose 1b
From tetra-O-acetyl-1-thio-b-D-glucopyranose (1.8 g, 5.3 mmol)
according to general procedure A yielding 1b (1.38 g, 2.61 mmol,
53%) as a yellow crystalline product.
Rf = 0.48 (PE/EtOAc, 1:1); ½a25D +7.5 (c 0.57, MeOH), lit.32 [a]D
+8.0 (c 1, CHCl3); mp = 156–157 C; 1H NMR (360 MHz, CDCl3) d
9.40 (s, 1H, OH), 8.30 (d, 2H, J = 7.9 Hz, H-ar), 7.62 (d, 2H,
J = 7.9 Hz, H-ar), 5.11–5.02 (m, 3H, H-2 H-3 H-4), 4.63 (d, 1H,
J = 9.2 Hz, H-1), 4.12 (dd, 1H, J = 3.8 and 11.9 Hz, H-6), 4.01 (dd,
1H, J = 2.6 Hz, H-60), 3.24 (ddd, 1H, H-5), 2.11, 2.07 (2s, 6H, CH3CO),
1.99 (s, 6H, CH3CO); 13C NMR (90 MHz, CDCl3) d 170.6, 170.2 (2s,
CH3CO), 169.3 (s, 2C, CH3CO), 149.4 (C=N), 148.6, 139.2 (2s, CH-
ar), 129.8 (s, 2C, CH-ar), 123.5 (s, 2C, CH-ar), 81.3 (C-1), 75.8,
73.4, 70.1, 67.8 (4s, C-2 C-3 C-4 C-5), 61.8 (C-6), 20.7, 20.6 (2s,
2C, CH3CO), 20.4 (s, 2C, CH3CO); Anal. Calcd for C21H24N2O12S
(528.50): C, 47.73; H, 4.58; N, 5.30; S, 6.07. Found: C, 47.51; H,
4.76; N, 5.65; S, 5.99.
4.2.2. 2,3,4,6-Tetra-O-acetyl-1-S-(Z)-4-cyanobenzhydroximoyl-
1-thio-b-D-glucopyranose 1c
From tetra-O-acetyl-1-thio-b-D-glucopyranose (1.5 g, 4.1 mmol)
according to general procedure A yielding 1c (900 mg, 1.77 mmol,
48%) as a white crystalline product.
Rf = 0.19 (PE/EtOAc, 2:1); ½a25D +23 (c 0.28, MeOH); mp = 165–
167 C; 1H NMR (360 MHz, CDCl3) d 10.10 (s, 1H, OH), 7.80–7.70
(m, 4H, H-ar), 5.10–5.00 (m, 3H, H-2 H-3 H-4), 4.62 (d, 1H,
J = 9.2 Hz, H-1), 4.12 (dd, 1H, J = 3.8 and 11.9 Hz, H-6), 3.98 (dd,
1H, J = 2.6 Hz, H-60), 3.22 (ddd, 1H, H-5), 2.09, 2.05 (2s, 6H, CH3CO),
1.99 (s, 6H, CH3CO); 13C NMR (90 MHz, CDCl3) d 170.6, 170.1, (2s,
CH3CO), 169.3 (s, 2C, CH3CO), 149.0 (C=N), 137.5, 132.1 (2s, CH-
ar), 129.4 (s, 2C, CH-ar), 117.9 (s, 2C, CH-ar), 113.4 (CN), 81.1 (C-
1), 75.6, 73.4, 70.0, 67.7 (4s, C-2 C-3 C-4 C5), 61.7 (C-6), 20.6,
20.4 (2s, CH3CO), 20.3 (s, 2C, CH3CO); Anal. Calcd for C21H24N2O10S
(508.11): C, 51.96; H, 4.76; N, 5.51; S, 6.31. Found: C, 51.71; H,
4.88; N, 5.32; S, 6.11.Please cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (2E
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4.2.3. 2,3,4,6-Tetra-O-acetyl-1-S-(Z)-4-methoxybenzhydroximoyl-
1-thio-b-D-glucopyranose 1e
From tetra-O-acetyl-1-thio-b-D-glucopyranose (1.63 g, 4.47 mmol)
according to general procedure A yielding 1e (1.17 g, 2.28 mmol,
51%) as a white crystalline product.
Rf = 0.27 (PE/EtOAc, 1:1); ½a25D +29 (c 0.44, CH2Cl2); lit.32 [a]D
+13 (c 1, CHCl3); mp = 157–161 C lit.32 mp = 150 C; 1H NMR
(360 MHz, CDCl3) d 9.46 (s, 1H, OH), 7.46 (d, 2H, J = 7.9 Hz, H-ar),
6.93 (d, 2H, J = 7.9 Hz, H-ar), 5.10–4.99 (m, 3H, H-2 H-3 H-4),
4.50 (d, 1H, J = 10.5 Hz, H-1), 4.12 (dd, 1H, J = 3.6 and 11.9 Hz, H-
6), 3.98 (dd, 1H, J = 1.2 Hz, H-60), 3.86 (s, 3H, OCH3), 3.13 (ddd,
1H, H-5), 2.10, 2.04 (2s, 6H, CH3CO), 1.96 (s, 6H, CH3CO); 13C
NMR (90 MHz, CDCl3) d 170.6, 170.2 (2s, CH3CO), 169.2 (s, 2C,
CH3CO), 160.8 (C@N), 152.2, 130.3, 124.5 (2s, CH-ar), 113.7 (2s,
CH-ar), 81.4 (C-1), 75.3, 73.7, 69.4, 67.8 (4s, C-2 C-3 C-4 C5), 61.8
(C-6), 55.3 (OCH3), 20.6, 20.5, 20.4, 20.3 (4s, CH3CO); Anal. Calcd
for C22H27NO11S (513.52): C, 51.46; H, 5.30; N, 5.51; S, 6.24. Found:
C, 51.62; H, 5.46; N, 5.50; S, 6.01.
4.2.4. 2,3,4,6-Tetra-O-acetyl-1-S-(Z)-3,4,5-trimethoxybenzhydr-
oximoyl-1-thio-b-D-glucopyranose 1f
Tetra-O-acetyl-1-thio-b-D-glucopyranose (553 mg, 1.57 mmol)
dissolved in CH2Cl2 (30 mL) was reacted with 3,4,5-trim-
ethoxybenzhydroximoyl chloride (4.92 mmol, 3 equiv) upon stir-
ring at room temperature in the presence of NEt3 (3 mL,
22 mmol, 14 equiv) and under argon. After the reaction was over
(30 min), aqueous washings and concentration afforded a crude
oil which was puriﬁed by column chromatography (PE/EtOAc
1:1, then 2:3), yielding 1f (770 mg, 1.35 mmol, 85% yield) as a col-
orless foam.
Rf = 0.23 (PE/EtOAc, 1:1); ½a20D +27.8 (c 1, CH2Cl2); 1H NMR
(300 MHz, CDCl3) d 9.12 (s, 1H, OH), 6.75 (s, 2H, H-ar), 5.03 (m,
3H, H-2 H-3 H-4), 4.68 (d, 1H, J = 9.5 Hz, H-1), 4.06 (dd, 1H,
J = 3.8 and 12.5 Hz, H-6), 3.93 (dd, 1H, J = 2.3 Hz, H-60), 3.84 (s,
9H, OMe), 3.19 (ddd, 1H, H-5), 2.00, 1.99, 1.94, 1.92 (4s, 12H,
CH3CO); 13C NMR (75 MHz, CDCl3) d 171.1, 170.7, 170.2, 169.7
(4s, CH3CO), 153.6 (s, 2C), 151.8 (C@N), 140.0, 128.4, 106.8 (s, 2C,
CH-ar), 82.1 (C-1), 76.2 (C-5), 74.1, 70.8, 68.1 (3s, C-2 C-3 C-4),
* 61.8 (C-6), 21.0, 20.92, 20.91, 20.8 (4s, CH3CO); Anal. Calcd for
C24H31NO13S (573.57): H, 5.45; N, 2.44; O, 36.26. Found: H, 5.20;
N, 2.25; O, 35.46.
4.2.5. 2,3,4,6-Tetra-O-acetyl-1-S-(Z)-(4-phenyl)-benzhydroxi-
moyl-1-thio-b-D-glucopyranose 1g
From tetra-O-acetyl-1-thio-b-D-glucopyranose (1.94 g, 5.32 mmol)
according to general procedure A yielding 1g (1.20 g, 2.14 mmol,
40%) as a white crystalline product.
Rf = 0.28 (PE/EtOAc, 1:1); ½a25D +5.7 (c 0.17, MeOH); mp = 101–
103 C; 1H NMR (360 MHz, CDCl3) d 9.53 (s, 1H, OH), 7.72–7.63
(m, 6H, H-ar), 7.55–7.41 (m, 3H, H-ar), 5.16–5.00 (m, 3H, H-2 H-
3 H-4), 4.55 (d, 1H, J = 9.2 Hz, H-1), 4.25 (dd, 1H, J = 3.6 and
11.9 Hz, H-6), 4.15 (dd, 1H, J = 2.6 Hz, H-60), 3.15 (ddd, 1H, H-5),
2.12, 2.09, 2.01, 1.98 (4s, 12H, CH3CO); 13C NMR (90 MHz, CDCl3)
d 170.6, 170.2, 169.2 (4s, CH3CO), 151.9 (C@N), 142.7, 139.8,
131.9, 129.3, 128.9 (s, 2C), 127.8, 127.6, 127.3, 127.0 (s, 2C),
126.9 (CH-ar), 81.3 (C-1), 75.8, 73.7, 69.9, 67.8 (4s, C-2 C-3 C-4
C-5), 61.2 (C-6), 20.6, 20.5, 20.4, 20.3 (4s, CH3CO); Anal. Calcd for
C27H29NO10S (559.60): C, 57.95; H, 5.22; N, 2.50; S, 5.73. Found:
C, 57.71; H, 4.99; N, 2.66; S, 5.52.
4.2.6. 2,3,4,6-Tetra-O-acetyl-1-S-(Z)-2-naphthoyl-hydroximoyl-
1-thio-b-D-glucopyranose 1h23
From tetra-O-acetyl-1-thio-b-D-glucopyranose (875 mg,
2.40 mmol) according to general procedure A yielding 1h
(999 mg, 1.87 mmol, 78%) as a white crystalline product.009), doi:10.1016/j.bmc.2009.05.080
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4.2.7. 2,3,4,6-Tetra-O-acetyl-1-S-(Z)-isonicotinoyl-hydroximoyl-
1-thio-b-D-glucopyranose 1i
2,3,4,6-Tetra-O-acetyl-1-thio-b-D-glucopyranose (107 mg, 0.29
mmol) and 4-pyridyl-hydroximoyl chloride (250 mg, 1.59 mmol,
5.6 equiv) were introduced in a 25 mL ﬂask. After the ﬂask was
ﬂushed with argon, anhydrous dichloromethane (6 mL) and trieth-
ylamine (0.53 mL, 3.77 mmol, 13 equiv) were added with stirring.
After the dark brown solution was stirred for 30 min at room tem-
perature, the reaction was ﬁnished (TLC). The mixture, diluted with
dichloromethane (25 mL), was washed with a satd aq NaHCO3
solution (25 mL), then with water (25 mL). The organic layer was
dried (MgSO4) and concentrated under reduced pressure to afford
a crude yellow oil (245 mg) which was subjected to column chro-
matography (PE/EtOAc 2:3 gradually changed to 0:1, with 0.1%
Et3N) to afford an orange-colored solid. After treatment of a dichlo-
romethane solution with charcoal, 1i was obtained a white solid
upon ﬁltration and evaporation (112 mg, 0.23 mmol, 78% yield).
Rf = 0.12 (PE/EtOAc, 2:3); ½a20D +9.3 (c 1, CH2Cl2); mp = 139–
140 C; 1H NMR (300 MHz, CD3COCD3) d 11.61 (s, 1H, OH), 8.69
(dd, 2H, J = 1.6 and 4.4 Hz, H-ar), 7.56 (dd, 2H, H-ar), 5.23 (t, 1H,
J = 9.0 Hz H-3), 5.01 (t, 1H, H-2), 4.98 (t, 1H, H-4), 4.95 (d, 1H,
J = 10.0 Hz, H-1), 4.12 (dd, 1H, J = 5.5 and 12.5 Hz, H-6), 3.98 (dd,
1H, J = 2.3 Hz, H-60), 3.56 (ddd, 1H, H-5), 2.06, 2.02, 1.94, 1.92 (4s,
12H, CH3CO); 13C NMR (75 MHz, CD3COCD3) d 171.6, 171.1,
170.9, 170.8 (4s, CH3CO), 152.0 (s, 2C, CH-ar), 149.9 (C@N), 143.0,
124.9 (s, 2C, CH-ar), 82.5 (C-1), 77.3 (C-5), 75.0 (C-3), 72.1, 70.0
(2s, C-2 C-4),* 63.8 (C-6), 21.6, 21.5, 21.4, 21.3 (4s, CH3CO); HRMS
(FAB > 0) C20H25N2O10S [M+H]+ Calcd 485.1230, found 485.1233;
Anal. Calcd for C20H24N2O10S (484.28): C, 49.58; H, 4.99; N, 5.78;
O, 33.02; S, 6.62. Found: C, 49.51; H, 4.96; N, 5.70; O, 32.95.
4.2.8. 2,3,4,6-Tetra-O-acetyl-1-S-(Z)-isonicotinoyl-hydroximoyl-
1-thio-b-D-glucopyranose-N-oxide 1j
A solution of 1i (195 mg, 0.4 mmol) in chloroform (10 mL) was
cooled down to 0 C before the addition of m-chloroperbenzoic
acid (139 mg, 0.8 mmol, 2 equiv). After 8 h, TLC monitoring
showed two main polar products. After concentration under re-
duced pressure, the crude mixture was puriﬁed by ﬂash column
chromatography (EtOAc containing 0.1% Et3N gradually enriched
in MeOH from 0% to 6%) affording 1j (62 mg, 0.12 mmol, 30% yield)
as an orange solid. When the reaction was carried out with a lower
amount of m-CPBA (1 equiv), the yield was 25%.
Rf = 0.20 (EtOAc/MeOH, 9:1); ½a20D – 17.7 (c 0.53, MeOH); mp =
152 C darkening, 182 C decomposition; 1H NMR (300 MHz,
CD3COCD3) d 11.49 (s, 1H, OH), 8.07 (d, 2H, J = 7.2 Hz, H-ar), 7.50
(d, 2H, H-ar), 5.14 (t, 1H, J = 9.2 Hz, H-3), 4.98 (d, 1H, J = 10.1 Hz,
H-1), 4.89 (dd, 1H, J = 9.0 Hz, H-2), 4.88 (t, 1H, J = 9.7 Hz, H-4),
4.04 (dd, 1H, J = 5.5 and 12.4 Hz, H-6), 3.93 (dd, 1H, J = 2.3 Hz, H-
60), 3.68 (ddd, 1H, H-5), 1.92, 1.89, 1.83, 1.80 (4s, 12H, CH3CO);
13C NMR (75 MHz, CD3COCD3) d 170.2, 169.7, 169.4, 169.3 (4s,
CH3CO), 147.2 (C@N), 139.3 (s, 2C, CH-ar), (CIV not seen), 126.3
(s, 2C, CH-ar), 81.3 (C-1), 75.7 (C-5), 73.5 (C-3), 70.6 (C-2), 68.5
(C-4), 62.5 (C-6), 20.0 (m, 4C, CH3CO).
4.3. Deacetylation of O-peracetylated hydroximothioates
4.3.1. 1-S-(Z)-4-Nitrobenzhydroximoyl-1-thio-b-D-glucopyranose
2b
From compound 1b (200 mg, 0.38 mmol) according to general
procedure D yielding 2b (111 mg, 0.3 mmol, 82%) as a white crys-
talline product.
Rf = 0.12 (CHCl3/MeOH, 9:1); ½a25D +7.5 (c 0.56, MeOH), lit.32 ½a25D
+5 (c1,MeOH);mp = 184–187 C; 1HNMR (360 MHz, D2O) d8.27 (d,
2H, J = 7.9 Hz, H-ar), 7.72 (d, 2H, J = 7.9 Hz, H-ar), 4.24 (d, 1H,
J = 9.2 Hz, H-1), 3.58 (dd, 1H, J = 1.2 and 11.9 Hz, H-6), 3.51 (dd, 1H,
J = 3.9 Hz, H-60), 3.36, 3.28, 3.20 (3t, 3H, J = 9.2 Hz, H-2 H-3 H-4),Please cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (2E
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2.66 (ddd, 1H, H-5); 13C NMR (90 MHz, D2O) d 154.5 (C@N), 149.9,
140.1, 131.6 (s, 2C, CH-ar), 125.0 (s, 2C, CH-ar), 84.4 (C-1), 81.5,
78.5, 73.6, 70.3 (4s, C-2 C-3 C-4 C-5), 61.7 (C-6); Anal. Calcd for
C13H16N2O8S (360.34): C, 43.33; H, 4.48; N, 7.77; S, 8.90. Found: C,
43.44; H, 4.26; N, 7.16; S, 8.70.
4.3.2. 1-S-(Z)-4-Cyanobenzhydroximoyl-1-thio-b-D-glucopyranose
2c
From compound 1c (200 mg, 0.39 mmol) according to general
procedure D yielding (122 mg, 0.36 mmol, 86%) as a slightly col-
ored crystalline product.
Rf = 0.74 (CHCl3/MeOH, 7:3); ½a20D +23 (c 0.27, MeOH);
mp = 156–160 C; 1H NMR (360 MHz, D2O) d 7.80 (d, 2H,
J = 7.9 Hz, H-ar), 7.72 (d, 2H, J = 7.9 Hz, H-ar), 4.24 (d, 1H,
J = 9.2 Hz, H-1), 3.62 (dd, 1H, J = 5.3 and 13.2 Hz, H-6), 3.52 (dd,
1H, J = 1.3 Hz, H-60), 3.40–3.10 (m, 3H, H-2 H-3 H-4), 2.75 (ddd,
1H, H-5); 13C NMR (90 MHz, D2O) d 148.3 (C@N) 139.7, 132.8
(2s, CH-ar), 132.6 (2s, CH-ar), 119.5, 111.0 (CN), 83.3 (C-1), 80.0,
77.2, 72.6, 69.2 (4s, C-2 C-3 C-4 C-5), 60.4 (C-6); Anal. Calcd for
C14H16N2O6S (340.36): C, 49.41; H, 4.74; N, 8.23; S, 9.42. Found:
C, 49.24; H, 4.66; N, 8.42; S, 9.12.
4.3.3. 1-S-(Z)-4-Methoxybenzhydroximoyl-1-thio-b-D-glucopyr-
anose 2e
From compound 1e (300 mg, 0.58 mmol) according to general
procedure D yielding 2e (172 mg, 0.50 mmol, 86%) as a white crys-
talline product.
Rf = 0.70 (CHCl3/MeOH, 7:3); ½a25D – 85 (c 0.31, MeOH) lit.32 ½a25D
7 (c 1, MeOH); mp = 146–148 C; 1H NMR (360 MHz, D2O) d 7.45
(d, 2H, J = 7.9 Hz, H-ar), 7.04 (d, 2H, J = 7.9 Hz, H-ar), 4.22 (d, 1H,
J = 9.2 Hz, H-1), 3.85 (s, 3H, OCH3), 3.20–3.44 (m, 3H, H-2 H-3 H-
4), 3.68 (dd, 1H, J = 3.9 and 13.2 Hz, H-6), 3.56 (dd, 1H, J = 2.6 Hz,
H-60), 2.75 (ddd, 1H, H-5); 13C NMR (90 MHz, D2O) d 159.5
(C@N), 151.0, 130.9 (2s, CH-ar), 126.7 (2s, CH-ar), 113.8, 83.2 (C-
1), 79.9, 77.3, 72.3, 69.1 (4s, C-2 C-3 C-4 C-5), 60.4 (C-6), 55.6
(OCH3); Anal. Calcd for C14H19NO7S (345.37): C, 48.69; H, 5.55; N,
4.06; S, 9.28. Found: C, 48.44; H, 5.36; N, 4.26; S, 9.02.
4.3.4. 1-S-(Z)-(4-Phenyl)-benzhydroximoyl-1-thio-b-D-glucopyr-
anose 2g
From compound 1g (300 mg, 0.53 mmol) according to general
procedure D yielding (190 mg, 0.48 mmol, 90%) as a yellow oil.
Rf = 0.58 (CHCl3/MeOH, 7:3); ½a25D +5.7 (c 0.17, MeOH); 1H NMR
(360 MHz, DMSO-d6) d 8.40 (s, 1H, OH), 7.52–7.20 (m, 9H, H-ar),
4.98–4.51 (m, 4H, OH), 4.15 (d, 1H, J = 9.2 Hz, H-1), 4.24 (dd, 1H,
J = 5.8 and 13.2 Hz, H-6), 4.17 (dd, 1H, J = 2.6 Hz, H-60) 4.16–3.72
(m, 3H, H-2 H-3 H-4), 3.24 (ddd, 1H, H-5); 13C NMR (90 MHz,
DMSO-d6) d 151.1 (C@N), 140.9, 140.1, 129.9, 129.7, 129.6, 129.5,
129.3, 128.2, 128.1, 127.1, 126.9, 126.7, 84.4 (C-1), 80.4, 79.5, 73.8,
70.2 (4s, C-2 C-3 C-4 C-5), 60.9 (C-6); Anal. Calcd for C19H21NO6S
(391.45): C, 58.30; H, 5.41; N, 3.58; S, 8.19. Found: C, 58.14; H,
5.16; N, 3.12; S, 8.02.
4.3.5. 1-S-(Z)-2-Naphthoyl-hydroximoyl-1-thio-b-D-glucopyr-
anose 2h
From compound 1h (343 mg, 0.64 mmol) according to general
procedure D yielding (200 mg, 0.55 mmol, 85%) as a yellow oil.
Rf = 0.68 (CHCl3/MeOH, 7:3); ½a25D +4.4 (c 0.3, MeOH); mp = 150–
152 C; 1H NMR (360 MHz, D2O) d 8.04–7.54 (m, 7H, H-ar), 4.24 (d,
1H, J = 10.6 Hz, H-1), 3.56 (dd, 1H, J = 3.9 and 13.2 Hz, H-6), 3.44
(dd, 1H, J = 2.6 Hz, H-60) 3.36, 3.28, 3.12 (3t, 3H, J = 9.2 Hz, H-2 H-3
H-4), 2.52 (ddd, 1H, H-5); 13C NMR (90 MHz, D2O) d 148.3 (C@N),
139.7, 132.8, 132.7, 132.6 (s, 2C), 129.8 (s, 2C), 129.6, 119.6, 111.5,
83.3 (C-1), 80.1, 77.2, 72.6, 69.2 (4s, C-2C-3C-4C-5), 60.5 (C-6);Anal.
Calcd for C17H19NO6S (365.41): C, 55.88; H, 5.24; N, 3.83; S, 8.77.
Found: C, 55.74; H, 5.06; N, 3.52; S, 8.55.009), doi:10.1016/j.bmc.2009.05.080
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4.3.6. 1-S-(Z)-Isonicotinoyl-hydroximoyl-1-thio-b-D-
glucopyranose 2i
A solution composed of 1i (90 mg, 0.18 mmol) in a mixture of
MeOH (2 mL), water (2 mL) and NEt3 (0.4 mL) was treated accord-
ing to general procedure B. The residue was puriﬁed (RP-18: water)
to afford 2i (53 mg, 0.16 mmol, 90% yield) as a white solid.
Rf = 0.48 (EtOAc/MeOH, 4:1); ½a20D – 1.6 (c 1, H2O); mp = 140 C
darkening, 175 C decomposition; 1H NMR (300 MHz, D2O) d 8.62
(dd, 2H, J = 1.5 and 5.5 Hz, H-ar), 7.57 (dd, 2H, H-ar), 4.33 (d, 1H,
J = 9.8 Hz, H-1), 3.60 (dd, 1H, J = 2.4 and 12.7 Hz, H-6), 3.52 (dd,
1H, J = 4.9 Hz, H-60), 3.40 (t, 2H, J = 9.2 Hz, H-2), 3.31 (t, 1H,
J = 9.0 Hz, H-4), 3.25 (t, 1H, J = 8.7 Hz, H-3), 2.75 (ddd, 1H, H-5);
13C NMR (75 MHz, D2O) d 152.7 (C@N), 149.6 (s, 2C, CH-ar),
141.6, 124.3 (s, 2C, CH-ar), 83.1 (C-1), 80.3 (C-5), 77.3 (C-3), 72.5,
69.2 (2s, C-2, C-4),* 60.5 (C-6); Anal. Calcd for C12H16N2O6S, 0.5
H2O: C, 44.30; H, 5.27; N, 8.61; O; 31.97; S, 9.86. Found: C,
44.34; H, 5.26; N, 8.62; O, 32.45.
4.4. Spiro-cyclization
4.4.1. (1S)- and (1R)-2,3,4,6-Tetra-O-acetyl-1,5-anhydro-D-
glucitol-spiro[1.5]-3-(phenyl)-1,4,2-oxathiazole (1S)-3a and
(1R)-3a
When the spiro-cyclization was carried out with 1a (278 mg) in
CHCl3 in the presence of NBS (2 equiv) and DBU (1 equiv) according
to the general procedure C, TLC suggested a 1:1 ratio of the (1S)/
(1R)-epimers. Separation by repeated column chromatographies
with a gradient of PE/EtOAc as the mobile phase afforded (1S)-3a
(44 mg, 16%) and (1R)-3a (51 mg, 18%).
4.4.2. (1S)-2,3,4,6-Tetra-O-acetyl-1,5-anhydro-D-glucitol-
spiro[1.5]-3-(4-nitrophenyl)-1,4,2-oxathiazole (1S)-3b
A solution composed of 1b (827 mg, 1.56 mmol) and NBS
(557 mg,3.13 mmol)was treatedaccording to thegeneralprocedure
C to afford a ﬁrst crop of pure (1S)-3b (259 mg) as a white foam and
an additional crop (144 mg) of a mixture of (1S)-3b and (1R)-3b in a
7:93 ratio, respectively, (1H NMR). The calculated yields were,
respectively, 33% and 16% for the (1S)- and (1R)-epimers.
Rf = 0.62 (PE/EtOAc, 3:2); ½a20D +33 (c 1, CH2Cl2); 1H NMR
(300 MHz, CDCl3) d 8.31 (d, 2H, J = 9.0 Hz, H-ar), 7.87 (d, 2H,
J = 9.0 Hz, H-ar), 5.64 (m, 2H, H-2 H-3), 5.29 (m, 1H, H-4), 4.44
(ddd, 1H, J = 2.1, 3.6 and 10.3 Hz, H-5), 4.35 (dd, 1H, J = 3.6 and
12.7 Hz, H-60), 4.10 (dd, 1H, J = 2.1 and 12.7 Hz, H-6), 2.05, 2.07,
2.09, 2.10 (4s, 12H, CH3CO); 13C NMR (75 MHz, CDCl3) d 170.4
169.5, 169.3, 169.2, (4s, CH3CO), 154.4 (C@N), 149.3, 132.8, 128.8
(s, 2C, CH-ar), 124.1 (s, 2C, CH-ar), 123.4 (C-1), 70.9 (C-2 or C-3),
70.8 (C-5), 67.8 (C-2 or C-3), 67.2 (C-4), 60.9 (C-6), 20.6 (s, CH3CO),
20.4 (s, 3C, CH3CO); MS (ESI >0) m/z = 549.0 [M+Na]+, 1074.5
[2M+Na]+; HRMS (ESI >0) m/z = C21H22N2NaO12S [M+Na]+ calcd
549.0791, found 549.0792.
4.4.3. (1S)-2,3,4,6-Tetra-O-acetyl-1,5-anhydro-D-glucitol-
spiro[1.5]-3-(4-cyanophenyl)-1,4,2-oxathiazole (1S)-3c
A solution composed of 1c (680 mg, 1.34 mmol) and NBS
(476 mg, 2.67 mmol) was treated according to the general proce-
dure C to afford a ﬁrst crop of pure (1S)-3c (103 mg, 15%) as a white
foam and an additional crop (48 mg) of a mixture of (1S)-3c and
(1R)-3c in a 5:95 ratio, respectively, (1H NMR). The calculated
yields were, respectively, 15% and 7% for the (1S)- and (1R)-
epimers.
Rf = 0.49 (PE/EtOAc, 3:2); ½a20D +35 (c 1, CH2Cl2); 1H NMR
(300 MHz, CDCl3) d 7.79 (d, 2H, J = 8.7 Hz, CH-ar), 7.74 (d, 2H,
J = 8.7 Hz, CH-ar), 5.28 (m, 1H, H-4), 5.64 (m, 2H, H-2 H-3), 4.44
(ddd, 1H, J = 2.1, 3.6 and 10.3 Hz, H-5), 4.33 (dd, 1H, J = 3.6 and
12.7 Hz, H-60), 4.10 (dd, 1H, J = 2.1 and 12.7 Hz, H-6), 2.09 (s, 6H,
CH3CO), 2.04, 2.06 (2s, 6H, CH3CO); 13C NMR (75 MHz, CDCl3) dPlease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (2E
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170.4, 169.6, 169.29, 169.26, (4s, CH3CO), 154.5 (C@N), 132.6 (s,
2C, CH-ar), 131.2, 128.4 (s, 2C, CH-ar), 123.3 (C-1), 117.7, 115.1
(C„N), 70.84 (C-2 or C-3), 70.80 (C-5), 67.9 (C-2 or C-3), 67.3 (C-
4), 60.9 (C-6), 20.6 (CH3CO), 20.4 (s, 3C, CH3CO); MS (ESI >0) m/
z = 529.0 [M+Na]+, 1034.5 [2M+Na]+; HRMS (ESI > 0) m/
z = C22H22N2NaO10S [M+Na]+ calcd 529.0893, found 529.0898.
4.4.4. (1S)-2,3,4,6-Tetra-O-acetyl-1,5-anhydro-D-glucitol-
spiro[1.5]-3-(4-methoxyphenyl)-1,4,2-oxathiazole (1S)-3e
A solution composed of 1d (690 mg, 1.34 mmol) and NBS
(478 mg,2.68 mmol)was treatedaccording to thegeneralprocedure
C to afford a ﬁrst crop of pure (1S)-3e (372 mg) as a white foam and
an additional crop (218 mg) of a mixture of (1S)-3e and (1R)-3e in a
45:55 ratio, respectively, (1H NMR). The calculated yields were,
respectively, 69% and 17% for the (1S)- and (1R)-epimers.
Rf = 0.43 (PE/EtOAc, 3:2); ½a20D +52 (c 1, CH2Cl2); 1H NMR
(300 MHz, CDCl3) d 7.61 (d, 2H, J = 8.9 Hz, CH-ar), 6.94 (d, 2H,
J = 8.9 Hz, CH-ar), 5.62 (m, 2H, H-2 H-3), 5.26 (m, 1H, H-4), 4.41
(ddd, 1H, J = 2.0, 3.6 and 10.3 Hz, H-5), 4.34 (dd, 1H, J = 3.6 and
12.6 Hz, H-60), 4.07 (dd, 1H, J = 2.0 and 12.6 Hz, H-6), 3.85 (s, 3H,
OMe), 2.09, 2.08, 2.05, 2.03, (4s, 12H, CH3CO); 13C NMR (75 MHz,
CDCl3) d 170.6, 169.6, 169.5, 169.4 (4s, CH3CO), 162.2, 155.9
(C@N), 129.6 (s, 2C, CH-ar), 122.1 (C-1), 119.3, 114.3 (s, 2C, CH-
ar), 71.1 (C-2 or C-3), 70.5 (C-5), 67.9 (C-2 or C-3), 67.5 (C-4),
61.1 (C-6), 55.4 (OMe), 20.7 (CH3CO), 20.5 (s, 3C, CH3CO); MS
(ESI >0) m/z = 511.8 [M+H]+, 534.0 [M+Na]+, 1022.4 [2M+H]+,
1044.6 [2M+Na]+; HRMS (ESI >0) m/z = C22H25NNaO11S [M+Na]+
calcd 534.1046, found 534.1049.
4.4.5. (1R)-2,3,4,6-Tetra-O-acetyl-1,5-anhydro-D-glucitol-
spiro[1.5]-3-(3,4,5-trimethoxyphenyl)-1,4,2-oxathiazole (1R)-3f
Spiro-cyclization of 1f (580 mg) was attempted as before (NBS:
360 mg, 2 equiv; CHCl3, 25 mL) upon heating with a 60 W tungsten
lamp for 1 h. TLC showed that the transformation was not selec-
tive, yielding a multicomponent mixture. Workup and ﬂash col-
umn chromatography (PE then PE/EtOAc 1:1) of the crude
product (827 mg) afforded four fractions (90, 33, 21, 41 mg). Only
the third one was pure enough and led to exploitable NMR spectra
(COSY, HSQC), concluding to the presence of (1R)-3f.
1H NMR (300 MHz, CDCl3) d 6.93 (s, 2H, CH-ar), 5.59 (d, 1H,
J = 10.2 Hz, H-2), 5.27 (t, 1H, H-4), 5.10 (dd, 1H, J = 9.5 and
10.2 Hz, H-3), 4.35 (dd, 1H, J = 3.3 and 12.3 Hz, H-6), 4.10 (m, 2H,
H-5 H-60), 3.90 (s, 9H, OMe), 2.08, 2.07 (2s, 6H, CH3CO), 2.05 (s,
6H, CH3CO); 13C NMR (75 MHz, CDCl3) d 171.0, 170.3, 169.6,
168.9, (4s, CH3CO), 155.6 (C@N), 153.8 (s, 2C), 141.4, 127.4 (C-1),
122.8, 105.7 (s, 2C, CH-ar), 73.7 (C-3), 71.0 (C-5), 68.7 (C-2), 67.5
(C-4), 61.42 (C-6), 61.40 (OMe), 56.7 (s, 2C, OMe), 20.7 (CH3CO),
20.6 (s, 2C, CH3CO), 20.5 (CH3CO).
4.4.6. (1S)-2,3,4,6-Tetra-O-acetyl-1,5-anhydro-D-glucitol-
spiro[1.5]-3-[(4-phenyl)-phenyl]-1,4,2-oxathiazole (1S)-3g
A solution composed of 1g (200 mg, 357 lmol) and NBS
(127 mg, 715 lmol) was treated according to the general proce-
dure C to afford a ﬁrst crop of pure (1S)-3g (65 mg) as a white foam
and an additional crop (90 mg) of a mixture of (1S)-3g and (1R)-3g
in a 3:2 ratio, respectively. The calculated yields were, respectively,
61% and 18% for the (1S)- and (1R)-epimers.
Rf = 0.52 (PE/EtOAc, 3:2); ½a20D +45 (c 1, CH2Cl2); 1H NMR
(300 MHz, CDCl3) d 7.74 (d, 2H, J = 8.5 Hz, CH-ar), 7.65 (d, 2H,
J = 8.5 Hz, CH-ar), 7.57–7.63 (m, 2H, CH-ar), 7.37–7.50 (m, 3H,
CH-ar), 5.64 (m, 2H, H-2 H-3), 5.28 (m, 1H, H-4), 4.44 (ddd, 1H,
J = 2.0, 3.7 and 10.3 Hz, H-5), 4.36 (dd, 1H, J = 3.7 and 12.6 Hz, H-
60), 4.09 (dd, 1H, J = 2.0 and 12.6 Hz, H-6), 2.09, 2.06 (2s, 6H,
CH3CO), 2.04 (2s, 6H, CH3CO); 13C NMR (75 MHz, CDCl3) d 170.5,
169.6, 169.5, 169.4 (4s, CH3CO), 156.1 (C@N), 144.5, 139.6, 128.9
(s, 2C, CH-ar), 128.4 (s, 2C, CH-ar), 128.1 (CH-ar), 127.5 (s, 2C,009), doi:10.1016/j.bmc.2009.05.080
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CH-ar), 127.1 (s, 2C, CH-ar), 125.8, 122.4 (C-1), 71.0 (C-2 or C-3),
70.6 (C-5), 68.0 (C-2 or C-3), 67.5 (C-4), 61.1 (C-6), 20.7 (CH3CO),
20.5 (s, 3C, CH3CO); MS (ESI >0) m/z = 557.8 [M+H]+, 580.0
[M+Na]+, 1114.4 [2M+H]+, 1136.7 [2M+Na]+; HRMS (ESI >0) m/
z = C27H27NNaO10S [M+Na]+ calcd 580.1253, found 580.1252.
4.4.7. (1S)-2,3,4,6-Tetra-O-acetyl-1,5-anhydro-D-glucitol-
spiro[1.5]-3-(2-naphthyl)-1,4,2-oxathiazole (1S)-3h23
A solution composed of 1h (655 mg, 1.23 mmol) and NBS
(437 mg, 2.46 mmol) was treated according to the general proce-
dure C to afford a ﬁrst crop of pure (1S)-3h (181 mg) as a white
foam and an additional crop (160 mg) of a mixture of (1S)-3h
and (1R)-3h in a 1:2 ratio, respectively. The calculated yields were,
respectively, 36% and 16% for the (1S)- and (1R)-epimers.
4.4.8. (1R)-2,3,4,6-Tetra-O-acetyl-1,5-anhydro-D-glucitol-
spiro[1.5]-3-(4-pyridyl)-1,4,2-oxathiazole (1R)-3i
A solution composed of 1i (636 mg, 1.31 mmol) and NBS
(467 mg, 2.62 mmol) in anhydrous chloroform (30 mL) was treated
with for 30 min according to the general procedure C. TLC monitor-
ing showed the appearance of two main products (more mobile
than 1i) and two minor products. Workup and ﬂash chromatogra-
phy with petroleum ether EtOAc (containing 0.1% Et3N) 7:3 then
2:3 afforded a mixture (107 mg) with 3 components (NMR) some
being brominated (as shown by TLC using a speciﬁc staining re-
agent with ﬂuorescein), and (1R)-3i (190 mg, 0.39 mmol, 30%
yield) as a transparent solid which appeared labile at room temper-
ature and was kept at 0 C.
Rf = 0.63 (EtOAc); mp = 60–61 C; ½a20D +181.7 (c 0.9, CH2Cl2); 1H
NMR (300 MHz, CDCl3) d 8.75 (dd, 2H, J = 1.6 and 4.4 Hz, H-ar), 7.57
(dd, 2H, H-ar), 5.63 (d, 1H, J = 10.2 Hz, H-2), 5.28 (t, 1H, J = 9.7 Hz,
H-4), 5.11 (dd, 1H, J = 9.5 Hz, H-3), 4.34 (dd, 1H, J = 4.2 and 12.9 Hz,
H-6), 4.12 (m, 2H, H-5 H-60), 2.08, 2.07, 2.06, 2.05 (4s, 12H, CH3CO);
13C NMR (75 MHz, CDCl3) d 170.9, 170.3, 169.5, 168.9 (4s, CH3CO),
154.2 (C@N), 151.0 (s, 2C, CH-ar), 135.2, 128.3 (C-1), 122.0 (s, 2C,
CH-ar), 73.5 (C-3), 71.1 (C-5), 68.6 (C-2), 67.3 (C-4), 61.3 (C-6),
21.1, 21.0, 20.90, 20.92 (4s, CH3CO); Anal. Calcd for C20H22N2O10S
(482.46): C, 49.79; H, 4.60; N, 5.81; O, 33.16. Found: C, 50.07; H,
4.68; N, 5.55; O, 33.41.
4.5. Deacetylation of spiro-oxathiazoles
4.5.1. (1S)-1,5-Anhydro-D-glucitol-spiro[1.5]-3-(4-nitrophenyl)-
1,4,2-oxathiazole (1S)-4b
A solution composed of (1S)-3b (255 mg) was treated according
to general procedure D to afford (1S)-4b (124 mg, 71%) as a pale
yellow solid.
Rf = 0.43 (EtOAc/MeOH, 85:15); ½a20D +58.8 (c 1, DMSO);
mp = 182–183 C; 1H NMR (300 MHz, CD3OD, 50 C) d 8.30 (d,
2H, J = 8.9 Hz, CH-ar), 7.90 (d, 2H, J = 8.9 Hz, CH-ar), 3.92 (ddd,
1H, J = 2.3, 4.7 and 9.5 Hz, H-5), 3.90 (d, 1H, J = 9.5 Hz, H-2), 3.82
(dd, 1H, J = 2.3 and 12.2 Hz, H-60), 3.78 (t, 1H, J = 9.5 Hz, H-3),
3.76 (dd, 1H, J = 4.7 and 12.2 Hz, H-6), 3.53 (t, 1H, J = 9.5 Hz, H-
4); 13C NMR (75 MHz, CD3OD, 50 C) d 154.5 (C@N), 150.7, 135.3,
129.8 (s, 2C, CH-ar), 129.0, 125.2 (s, 2C, CH-ar), 77.7 (C-5), 76.2
(C-3), 73.0 (C-2), 70.8 (C-4), 62.2 (C-6); MS (ESI <0) m/z = 392.9
[M+Cl], 750.5 [2M+Cl]; HRMS (ESI <0) m/z = C13H14ClN2O8S
[M+Cl] calcd 393.0159, found 393.0158.
4.5.2. (1S)-1,5-Anhydro-D-glucitol-spiro[1.5]-3-(4-
cyanophenyl)-1,4,2-oxathiazole (1S)-4c
A solution composed of (1S)-3c (100 mg) was treated according
to general procedure D to afford (1S)-4c (56 mg, 84%) as a pale yel-
low foam.
Rf = 0.35 (EtOAc/MeOH, 85:15); ½a20D +36.3 (c 1, DMSO); 1H NMR
(300 MHz, CD3OD) d 7.85 (m, 4H, CH-ar), 3.86–3.93 (m, 1H, H-5),Please cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (2E
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3.89 (d, 1H, J = 9.6 Hz, H-2), 3.81 (dd, 1H, J = 2.3 and 12.3 Hz, H-
60), 3.70–3.78 (m, 2H, H-3 H-6), 3.51 (t, 1H, J = 9.0 Hz, H-4); 13C
NMR (75 MHz, CD3OD) d 155.8 (C@N), 134.0 (s, 2C, CH-ar), 133.7,
129.4 (s, 2C, CH-ar), 128.8 (C-1), 119.0, 115.6 (CN), 77.6 (C-5),
76.1 (C-3), 72.7 (C-2), 70.6 (C-4), 61.9 (C-6); MS (ESI <0) m/
z = 372.9 [M+Cl]; HRMS (ESI <0) m/z = C14H14ClN2O6S [M+Cl]
calcd 373.0261, found 373.0264.
4.5.3. (1S)-1,5-Anhydro-D-glucitol-spiro[1.5]-3-(4-ﬂuorophen-
yl)-1,4,2-oxathiazole (1S)-4d
Prepared by general procedure D from (1S)-3d (500 mg) to af-
ford (1S)-4d (392 mg, 79%) as a pale yellow solid.
Rf = 0.69 (CHCl3/MeOH, 7:3); ½a20D +51 (c 1.1, DMSO); mp = 192–
193 C; 1H NMR (360 MHz, DMSO-d6) d 7.73–7.69 (m, 2H, H-ar),
7.38–7.33 (m, 2H, H-ar), 3.72–3.62 (m, 3H, H-6 H-60 H-1), 3.53–
3.23 (m, 3H, H-2 H-3 H-5); 13C NMR (90 MHz, DMSO-d6) d 163.2,
154.7 (C@N), 130.8, 130.7, 128.3, 117.5, 117.2, 108.8 (C-1), 77.7,
75.3, 72.1, 70.1 (C-2 C-3 C-4 C-5), 61.2 (C-6); Anal. Calcd for
C13H14NO6S (331.32): C,47.13; H, 4.26; N, 4.23; S, 9.68. Found: C,
47.33; H, 4.09; N, 4.52; S, 9.45.
4.5.4. (1S)-1,5-Anhydro-D-glucitol-spiro[1.5]-3-(4-methoxyphe-
nyl)-1,4,2-oxathiazole (1S)-4e
A solution composed of (1S)-3e (370 mg) was treated according
to general procedure D to afford (1S)-4e (196 mg, 79%) as a pale
yellow solid.
Rf = 0.33 (EtOAc/MeOH, 85:15); ½a20D +43.4 (c 1, DMSO);
mp = 192–194 C; 1H NMR (300 MHz, DMSO-d6+eD2O) d 7.57 (d,
2H, J = 8.7 Hz, H-ar), 7.04 (d, 2H, J = 8.7 Hz, H-ar), 3.80 (s, 3H,
OMe), 3.43–3.71 (m, 5H), 3.24 (t, 1H, J = 9.4 Hz); 13C NMR
(75 MHz, DMSO-d6+eD2O) d 161.6, 154.6, 129.2 (s, 2C, CH-ar),
126.8, 119.8, 114.8 (s, 2C, CH-ar), 76.6, 74.3, 71.0, 69.1, 60.3 (C-
6), 55.6 (OMe); MS (ESI <0) m/z = 377.9 [M+Cl]; MS (ESI >0) m/
z = 365.9 [M+Na]+, 708.8 [2M+Na]+; HRMS (ESI >0) m/
z = C14H17NNaO7S [M+Na]+ calcd 366.0623, found 366.0621.
4.5.5. (1S)-1,5-Anhydro-D-glucitol-spiro[1.5]-3-[(4-phenyl)-
phenyl]-1,4,2-oxathiazole (1S)-4g
A solution composed of (1S)-3g (65 mg) was treated according
to general procedure D to afford (1S)-4g (44 mg, 97%) as a pale yel-
low foam.
Rf = 0.32 (EtOAc/MeOH,85:15); ½a20D +39.4 (c0.6,DMSO); 1HNMR
(500 MHz, CD3OD) d 7.79 (d, 2H, J = 8.3 Hz, CH-ar), 7.73 (d, 2H,
J = 8.3 Hz, H-ar), 7.65–7.69 (m, 2H, H-ar), 7.36–7.52 (m, 3H, CH-ar),
3.92 (ddd, 1H, J = 2.3, 4.6 and 9.9 Hz, H-5), 3.88 (d, 1H, J = 9.9 Hz,
H-2), 3.82 (dd, 1H, J = 2.3 and 12.3 Hz, H-60), 3.73–3.79 (m, 2H, H-3
H-6), 3.52 (t, 1H, J = 9.9 Hz, H-4), 13C NMR (125 MHz, CD3OD) d
62.0 (C-6), 70.8 (C-4), 72.8 (C-2), 76.2 (C-3), 77.5 (C-5), 127.8 (C-1),
128.1 (s, 2C, CH-ar), 128.5 (s, 2C, CH-ar), 129.2 (s, 2C, CH-ar), 129.3
(s, 2C, CH-ar), 130.1 (s, 2C, CH-ar), 133.8, 141.1, 145.4, 157.2
(C@N); MS (ESI <0) m/z = 423.9 [M+Cl]; HRMS (ESI <0) m/
z = C19H19ClNO6S [M+Cl] calcd 424.0622, found 424.0623.
4.5.6. (1S)-1,5-Anhydro-D-glucitol-spiro[1.5]-3-(2-naphthyl)-
1,4,2-oxathiazole (1S)-4h23
A solution composed of (1S)-3h (180 mg) was treated according
to general procedure D to afford (1S)-4h (116 mg, 94%) as a pale
yellow solid.
4.5.7. (1R)-1,5-Anhydro-D-glucitol-spiro[1.5]-3-(4-pyridyl)-
1,4,2-oxathiazole (1R)-4i
(1R)-3i (115 mg, 0.24 mmol) was treated according to general
procedure B (NEt3, MeOH, H2O) to afford (1R)-4i (71 mg,
0.22 mmol, 95% yield) as a white solid.
Rf = 0.40 (EtOAc/MeOH, 4:1); ½a20D 4 (c 0.3, DMF); mp = 174–
175 C; 1H NMR (300 MHz, D2O) d 8.63 (dd, 2H, J = 1.8 and009), doi:10.1016/j.bmc.2009.05.080
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4.5 Hz, H-ar), 7.70 (dd, 2H, H-ar), 3.94 (d, 1H, J = 10.2 Hz, H-2), 3.81
(m, 3H, H-5 H-6 H-60), 3.60 (t, 1H, J = 9.1 Hz, H-4), 3.40 (dd, 2H,
J = 9.0 Hz, H-3); 13C NMR (75 MHz, D2O) d 156.2 (C@N), 150.0 (s,
2C, CH-ar), 135.9, 130.8 (C-1), 122.6 (s, 2C, CH-ar), 76.7 (C-3),
75.5 (C-5), 71.6 (C-2), 68.5 (C-4), 60.2 (C-6); HRMS (FAB > 0) m/
z = C12H15N2O6S [M+H]+ calcd 315.0651, found 315.0655.
4.6. Synthesis of N-glycosyl-amidoximes
4.6.1. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-
benzamidoxime 8a
Prepared according to general procedure E to afford 8a in 57%
yield as a syrup. The product decomposed rapidly during the
NMR spectroscopic measurement.
4.6.2. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-4-
nitrobenzamidoxime 8b
Prepared according to general procedure E to afford 8b
(880 mg) in 64% yield.
[a]D +20 (c 1.2, CHCl3); mp = 183–185 C; 1H NMR (360 MHz,
CDCl3) d 9.36 (s, 1H, OH), 8.25 (d, 2H, J = 9.1 Hz, H-ar), 7.72 (d,
2H, J = 8.4 Hz, H-ar), 6.20 (d, 1H, NH), 5.12 (t, 1H, J = 9.6 Hz, H-2),
5.03 (t, 1H, J = 9.4 Hz, H-3), 4.97 (t, 1H, J = 9.2 Hz, H-4), 4.31 (t,
1H, J = 9.9 Hz, H-1), 4.12 (dd, 1H, J = 5.1 Hz, H-6), 4.02 (dd, 1H,
J = 11.8 Hz, H-60), 3.38 (ddd, 1H, J = 2.8 Hz, H-5), 2.09, 2.05, 1.97,
1.95 (4s, 12H, CH3CO); 13C NMR (90 MHz, CDCl3) d 170.4, 170.1,
170.0, 169.4 (4s, CH3CO), 151.9 (NHC(@NOH)Ar), 148.7 (CNO2),
136.5 (N2C–C), 129.5, 123.6, 82.5 (C-1), 72.9, 72.5, 70.6, 68.3 (4s,
C-2 C-3 C-4 C-5), 62.1 (C-6), 20.5, 20.6, 20.4 (3s, 4C, CH3CO); Anal.
Calcd for C21H25N3O12 (511.45): C, 49.32; H, 4.93; N, 8.22. Found: C,
50.02; H, 5.03; N, 8.16.
4.6.3. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-4-
cyanobenzamidoxime 8c
Prepared according to general procedure E to afford 8c (245 mg)
in 18% yield.
Optimised synthesis of 8c: 2,3,4,6-Tetra-O-acetyl-b-D-glucopyr-
anosyl azide 7 (100 mg, 0.26 mmol) was dissolved in dry dichloro-
methane (1 mL) and trimethyl phosphine (0.268 mL, 1 M in
toluene) was added with stirring. During gas evolution, the reagent
solution was freshly prepared by adding triethylamine to a solu-
tion of p-cyanophenyl hydroximinoyl chloride (153 mg,
0.26 mmol) in dry dichloromethane (1 mL) causing the formation
of triethylamine hydrochloride precipitate. When TLC showed
complete transformation of the starting material 7 (15 min),
the reagent solution was added to the mixture. After 10 min, the
reaction mixture was poured into water and was worked up as de-
scribed in general procedure E to afford 8c (78 mg, 60% yield).
[a]D +9.8 (c 0.2, CDCl3); mp = 120–123 C; 1H NMR (300 MHz,
CDCl3) d 8.50 (s, 1H, OH), 7.71 (d, 2H, J = 8.6 Hz, H-ar), 7.65 (d,
2H, J = 8.3 Hz, H-ar), 6.16 (d, 1H, J = 10.4 Hz, NH), 5.14 (t, 1H,
J = 9.4 Hz, H-3 or H-4), 5.03 (t, 1H, J = 8.8 Hz, H-2), 4.99 (t, 1H,
J = 9.4 Hz, H-3 or H-4), 4.31 (dd, 1H, J = 8.8 Hz, H-1), 4.10 (d, 1H,
J = 6.6 Hz, H-6), 4.02 (dd, 1H, J = 12.5 Hz, H-60), 3.39 (ddd, 1H,
J = 2.7 Hz, H-5), 2.09, 2.06, 2.02, 1.99 (4s, 12H, CH3CO); 13C NMR
(75 MHz, CDCl3) d 170.4, 170.2, 170.0 (3s, 4C, CH3CO), 152.3
(NHC(@NOH)Ar), 134.7 (N2C–C), 132.3, 129.2, 128.9 (C–CN),
113.9 (CN), 82.5 (C-1), 72.9 (C-5), 72.4, 70.7, 68.3 (C-2 C-3 C-4),
62.1 (C-6), 21.0, 20.7, 20.6, 20.5 (4s, CH3CO); Anal. Calcd for
C22H25N3O10 (491.46): C, 53.77; H, 5.13; N, 8.55. Found: C, 53.43;
H, 5.09; N, 8.62.
4.6.4. N-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)-C-(2-
naphthyl)-amidoxime 8h
Prepared according to the general procedure E to afford 8h
(92 mg) in 6% yield as a brownish foamwhich decomposed rapidly.Please cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (2E
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4.7. Deacetylation of N-glycosyl-amidoximes
4.7.1. N-(b-D-Glucopyranosyl)-4-nitrobenzamidoxime 9b
A few drops of NaOMe (2.5 M in MeOH) were added to a solu-
tion of 8b (100 mg, 0.19 mmol) in dry methanol (7 mL). The reac-
tion mixture was stirred at rt for 5 min before the addition of
cation exchange resin Amberlyst 15 (H+ form). The resin was ﬁl-
tered off and the solvent was removed. The residue was puriﬁed
by crystallization to give 56 mg (83%) of 9b.
[a]D 56 (c 1.3, DMSO); mp = 165–168 C; 1H NMR (300 MHz,
DMSO-d6) d 10.39 (s, 1H, OH), 8.22 (d, 2H, J = 8.4 Hz, H-ar), 7.91
(s, 2H, J = 8.2 Hz, H-ar), 6.40 (d, 1H, J = 9.84 Hz, NH), 5.1–4.65 (m,
4H, OH), 4.00–2.80 (m, 7H, H-1 H-2 H-3 H-4 H-5 H-6 H-60); 13C
NMR (75 MHz, DMSO-d6) d 152.0 (CNO2), 147.6 (N = CN), 138.5
(N2C–C), 129.6, 123.1, 83.8 (C-1), 78.1, 77.3, 72.8, 70.1 (4s, C-2 C-
3 C-4 C-5), 61.0 (C-6); Anal. Calcd for C13H17N3O8 (343.30): C,
45.48; H, 4.99; N, 12.24. Found: C, 46.02; H, 5.25; N, 11.87.
4.7.2. N-(b-D-Glucopyranosyl)-4-cyanobenzamidoxime 9c
A few drops of NaOMe (2.5 M in MeOH) were added to a solu-
tion of 8c (90 mg, 0.18 mmol) in dry methanol (9 mL). The reaction
mixture was stirred at rt for 25 min before the addition of cation
exchange resin Amberlyst 15 (H+ form). The resin was ﬁltered off
and the solvent was removed to give 48 mg (81%) of 9c as a syrup.
[a]D 132 (c 0.6, MeOH); 1H NMR (360 MHz, CD3OD) d 7.65 (d,
2H, J = 9.2 Hz, H-ar), 7.39 (d, 2H, J = 7.9 Hz, H-ar), 3.55 (t, 1H,
J = 11.8 Hz), 3.40–3.1 0(m, 5H); 13C NMR (90 MHz, CD3OD) d
156.4 (N–C@N), 134.6 (N2C–C), 124.9, 119.9 (NC–C), 108.1 (CN),
84.6 (C-1), 79.6, 78.6, 74.2, 71.5 (4s, C-2 C-3 C-4 C-5), 62.9 (C-6);
Anal. Calcd for C14H17N3O6 (323.31): C, 52.01; H, 5.30; N, 13.00.
Found: C, 52.52; H, 5.23; N, 12.65.
4.8. N-(Phenyl-nitrosomethylene)-2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosyl amine 10b
Photolysis of 8b with a 60 W heating lamp using 4 equiv of NBS in
one portion: A solution of 8b (200 mg, 0.39 mmol) in dry chloro-
form (8 mL) was placed in a 100 mL erlenmeyer ﬂask equipped
with a reﬂux condenser and NBS (278 mg, 1.56 mmol) was added
in one portion. The mixture was irradiated with a 60 Wwhite heat-
ing lamp from a distance of 1 cm. After 15 min, chloroform was
added (30 mL), the mixture was washed with 5% aq Na2SO3, satd
aq NaHCO3 and water. The organic layer was dried (Na2SO4), ﬁl-
tered and the solvent was removed under vacuo. The residue was
puriﬁed by column chromatography (EtOAc/hexane, 1:4) affording
10b as syrup in 30% yield (58 mg). Traces of 12b (3%) were also
detected in the crude product by NMR spectroscopy.
Compound 10b: [a]D +22 (c 0.4, CHCl3); 1H NMR (300 MHz,
CDCl3) d 8.39 (d, 2H, J = 8.3 Hz, H-ar), 8.05 (d, 2H, J = 8.9 Hz, H-
ar), 5.32 (d, 1H, J = 9.8 Hz, H-1), 5.23 (t, 1H, J = 9.5 Hz, H-3), 4.83
(t, 2H, J = 9.4 Hz, H-2 H-4), 4.44 (dd, 1H, J = 12.9 Hz, H-6), 4.13
(dd, 1H, J = 6.0 Hz, H-60), 3.90 (ddd, 1H, J = 1.9 Hz, H-5), 2.16,
2.01, 1.99, 1.93 (4s, 12H, CH3CO); 13C NMR (75 MHz, CDCl3) d
170.2, 169.5, 169.4, 169.2 (4s, CH3CO), 157.3 (N2C–C), 156.6
(NC@N), 150.1 (CNO2), 131.5, 123.7, 82.0 (C-1), 75.3, 72.2, 68.7,
66.8 (C-2 C-3 C-4 C-5), 61.0 (C-6), 20.7, 20.4, 20.3, 20.2 (4s, CH3CO);
Anal. Calcd for C21H23N3O12 (509.43): C, 49.51; H, 4.55; N, 8.25.
Found: C, 49.48; H, 4.76; N 8.22.
4.9. 3-(4-Nitrophenyl)-5-(D-gluco-1,2,3,5-tetraacetoxy-4-
hydroxypentyl)-1,2,4-oxadiazole 11b
Photolysis of 8b with a 375 W heating lamp using 4 equiv of NBS in
one portion: A solution of 8b (200 mg, 0.39 mmol) in dry chloro-
form (12 mL) was placed in a 100 mL erlenmeyer ﬂask equipped
with a reﬂux condenser and NBS (278 mg, 1.56 mmol, 4 equiv)009), doi:10.1016/j.bmc.2009.05.080
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was added in one portion. The mixture was irradiated with a
375W white heating lamp from a distance of 1 cm. After 2 h, the
mixture was diluted with chloroform (30 mL), washed with 5%
aq Na2SO3, satd aq NaHCO3 and water. The organic layer was dried
(Na2SO4), ﬁltered and the solvent was removed under vacuo. The
residue was puriﬁed by column chromatography (EtOAc/hexane,
1:4) affording 12b (13 mg, 13%) and 11b (20 mg, 20%) as a syrup.
Compound 11b: [a]D +26.2 (c 0.26, CHCl3); 1H NMR (400 MHz,
CDCl3) d 8.33 (d, 2H, J = 8.9 Hz, H-ar), 8.24 (d, 2H, J = 8.8 Hz, H-
ar), 6.16 (d, 1H, J = 6.7 Hz, H-2), 5.73 (dd, 1H, J = 3.1 and 7.3 Hz,
H-4), 5.20–5.17 (m, 1H, H-5), 3.53 (dd, 1H, J = 3.6 and 11.9 Hz, H-
6), 3.39 (dd, 1H, J = 6.4 Hz, H-60), 2.18, 2.11, 2.10, 2.08 (4s, 12H,
CH3CO); 13C NMR (100 MHz, CDCl3) d 174.3 (C-1), 169.5, 169.4,
169.3, 169.0 (4s, CH3CO), 166.9 (NC@N), 149.6 (CNO2), 131.8 (C–
CN2), 128.5, 124.1, 69.6, 69.2, 68.6 (C-2 C-3 C-4), 65.7 (C-6), 30.2
(C-5), 20.6, 20.5, 20.3, 20.2 (4s, CH3CO); MS (FAB > 0) m/z = 663.7
[M+dihydroxybenzoic acid]+; Anal. Calcd for C21H23N3O12
(509.43): C, 49.51; H, 4.55; N, 8.25. Found: C, 49.76, H 4.58, N 8.17.
4.10. 3-(4-Nitrophenyl)-5-(D-xylo-1,2,3,5-tetraacetoxy-4-
oxopentyl)-1,2,4-oxadiazole 12b
Photolysis of 8bwith a 60W heating lamp using 4 equiv of NBS in 4
portions: A solution of 8b (1 g, 1.96 mmol) in dry chloroform
(40 mL) was placed in a 250 mL erlenmeyer ﬂask equipped with
a reﬂux condenser and NBS (348 mg, 1.96 mmol, 1 equiv) was
added. The mixture was irradiated with a 60 Wwhite heating lamp
from a distance of 1 cm. After 30 min, NBS (348 mg, 1.96 mmol,
1 equiv) was added to the reaction mixture. An additional 2 equiv
of NBS were added in two portions after 105 min and 135 min,
respectively. After 2 h 45 min total reaction time, the mixture
was diluted with chloroform (120 mL), washed with 5% aq Na2SO3,
satd aq NaHCO3 and water. The organic layer was dried (Na2SO4),
ﬁltered and the solvent was removed under vacuo. The residue
was puriﬁed by column chromatography (EtOAc/hexane, 1:4)
affording 12b as a sole syrupy product in 45% yield (447 mg).
Compound 12b: [a]D +19.4 (c 0.3, CHCl3); 1H NMR (300 MHz,
CDCl3) d 8.32 (d, 2H, J = 10.1 Hz, H-ar), 8.22 (d, 2H, J = 9.1 Hz, H-
ar), 6.27 (d, 1H, J = 5.9 Hz, H-2), 5.90 (dd, 1H, J = 3.7 Hz, H-3),
5.54 (d, 1H, H-4), 4.87 (d, 1H, J = 17.3 Hz, H-6), 4.72 (d, 1H, H-60),
2.19, 2.13, 2.12, 2.01 (4s, 12H, CH3CO); 13C NMR (75 MHz, CDCl3)
d 197.1 (C-5), 174.3 (C-1), 169.7, 169.4, 169.2, 168.9 (4s, CH3CO),
167.0 (N2CAr), 149.6 (CNO2), 131.7 (N2C–C), 128.5, 124.1, 73.7 (C-
3), 69.5 (C-4), 66.4 (C-6), 65.4 (C-2), 23.1, 20.2, 20.1 (3s, 4C,
CH3CO); MS (FAB > 0) m/z = 508 [M+H]+; Anal. Calcd for
C21H21N3O12 (507.41): C, 49.71; H, 4.17; N, 8.28. Found: C, 49.58;
H, 4.23; N, 8.24.
4.11. (1R,2S,3R,4R)-1,2,3,5-Tetra-O-benzyl-1-C-[3-(4-methoxy-
phenyl)-4N-oxido-1,2,4-oxadiazole-5-yl]pentitol 15
A solution of Et3N (240 lL, 1.72 mmol, 12 equiv) in toluene
(2 mL) was added dropwise over 8 h (syringe pump) to a solution
of hydroximolactone 13 (80 mg, 0.14 mmol) and a-chloro-p-meth-
oxybenzaldoxime (210 mg, 1.15 mmol, 8 equiv) in reﬂuxing tolu-
ene (15 mL). After 24 h reﬂux, TLC showed a partial conversion of
13 into several products. After concentration, the residue was puri-
ﬁed by column chromatography (PE/EtOAc, 7:3) to afford unre-
acted 13 (33 mg) then 15 (13 mg, 13% isolated yield). Based on
the converted starting material, the calculated yield was 22%.
Compound 15: Rf = 0.55 (EP/EtOAc, 7:3); 1H NMR (500 MHz,
CDCl3) d 7.15–7.38 (m, 22H, H-ar), 6.88 (d, 2H, J = 8.7 Hz, H-ar),
4.75 (d, 1H, J = 12.2 Hz, CH2Ph), 4.66 (m, 2H, H-5 CH2Ph), 4.59 (d,
1H, J = 12.4 Hz, CH2Ph), 4.55 (m, 3H, CH2Ph), 4.47 (br s, 1H, CH2Ph),
4.41 (d, 1H, J = 11.8 Hz, CH2Ph), 4.18 (br s, 1H, H-2), 3.96 (m, 1H, H-
3), 3.84–3.88 (m, 2H, H-4 H-6), 3.79 (s, 4H, H-60 OCH3); 13C NMRPlease cite this article in press as: Nagy, V.; et al. Bioorg. Med. Chem. (2E
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(125 MHz, CDCl3) d 156.3, 154.2 (NCO), 140.8 (NC@N), 137.8,
137.4, 137.0, 136.6, 130.1, 127.0–128.6 (m, 16C, CH-ar), 121.4 (s,
2C, CH-ar), 114.2 (s, 2C, CH-ar), 80.8 (C-3), 77.2 (C-4), 77.1 (C-5),
73.4 (CH2Ph), 73.0 (CH2Ph), 72.9 (C-2), 71.7 (CH2Ph), 71.0 (CH2Ph),
67.7 (C-6), 55.5 (OCH3); MS (ESI >0) m/z = 703.0 [M+H]+, 725.0
[M+Na]+, 1404.9 [2M+H]+, 1426.9 [2M+Na]+; HRMS (ESI >0) m/
z = C42H43N2O8 [M+H]+ calcd 703.3019; found 703.3022.
4.12. Enzymatic methods
Glycogen phosphorylase b was prepared from rabbit skeletal
muscle according to the method of Fischer and Krebs,45 using dithi-
othreitol instead of L-cysteine, and recrystallized at least three
times before use. Kinetic experiments were performed in the direc-
tion of glycogen synthesis as described previously.18 Kinetic data
for the inhibition of rabbit skeletal muscle glycogen phosphorylase
were collected using different concentrations of a-D-glucose-1-
phosphate (2–20 mM), constant concentrations of glycogen (1%
w/v) and AMP (1 mM), and various concentrations of inhibitors.
Inhibitors were dissolved in dimethyl sulfoxide (DMSO) and di-
luted in the assay buffer (50 mM triethanolamine, 1 mM EDTA
and 1 mM dithiothreitol) so that the DMSO concentration in the as-
say should be lower than 1%. The enzymatic activities were pre-
sented in the form of double-reciprocal plots (Lineweaver–Burk)
applying a nonlinear data analysis program. The inhibitor con-
stants (Ki) were determined by Dixon plots, by replotting the
slopes from the Lineweaver-Burk plots against the inhibitor con-
centrations.26,30 The means of standard errors for all calculated ki-
netic parameters averaged to less than 10%.
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